Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Moderna, Inc. insider-related entities reported an option exercise and share sale. On May 21, 2026, Flagship Pioneering, LLC exercised stock options to acquire 9,263 shares of Moderna common stock at $19.15 per share, from options that were fully vested and set to expire on August 10, 2026.
That same day, Flagship Pioneering conducted an open-market sale of 9,263 shares of common stock at an average price of $46.84 per share, leaving 3,924 shares of common stock held indirectly by Flagship Pioneering afterward. The filing also shows 2,224,015 shares held directly by Noubar Afeyan and additional indirect holdings of 747,897 shares by Flagship Ventures Fund IV-Rx, L.P. and 3,880,328 shares by Flagship Ventures Fund IV, L.P. The reporting person is the ultimate control person of these entities and disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 9,263 shares ($433,879)
Net Sell
6 txns
Insider
AFEYAN NOUBAR
Role
null
Sold
9,263 shs ($434K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 9,263 | $0.00 | -- |
| Exercise | Common Stock | 9,263 | $19.15 | $177K |
| Sale | Common Stock | 9,263 | $46.84 | $434K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Indirect, By Flagship Pioneering, LLC);
Common Stock — 13,187 shares (Indirect, By Flagship Pioneering, LLC);
Common Stock — 2,224,015 shares (Direct, null)
Footnotes (1)
- On May 21, 2026, Flagship Pioneering, LLC ("Flagship Pioneering") exercised options to purchase 9,263 shares of the Issuer's Common Stock at $19.15 per share, which options were set to expire on August 10, 2026. The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The securities are held directly by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The securities are held directly by Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The options were fully vested and exercisable.
Key Figures
Shares sold: 9,263 shares
Sale price: $46.84 per share
Option exercise price: $19.15 per share
+4 more
7 metrics
Shares sold
9,263 shares
Open-market sale of common stock on May 21, 2026
Sale price
$46.84 per share
Average price for 9,263 common shares sold
Option exercise price
$19.15 per share
Exercise price for 9,263 stock options
Shares remaining at Flagship Pioneering
3,924 shares
Indirect Moderna common stock held after transactions
Direct shares held by Afeyan
2,224,015 shares
Common stock held directly following reported transactions
Indirect shares via Flagship Fund IV
3,880,328 shares
Common stock held by Flagship Ventures Fund IV, L.P.
Indirect shares via Flagship Fund IV-Rx
747,897 shares
Common stock held by Flagship Ventures Fund IV-Rx, L.P.
Key Terms
open-market sale, derivative security, stock option (Right to Buy), pecuniary interest, +1 more
5 terms
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
stock option (Right to Buy) financial
"Stock Option (Right to Buy)"
pecuniary interest financial
"disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein"
beneficial ownership financial
"disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What stock options were exercised in the Moderna (MRNA) Form 4?
Flagship Pioneering, LLC exercised stock options covering 9,263 Moderna common shares at a $19.15 exercise price. The options were fully vested and exercisable and were scheduled to expire on August 10, 2026, prompting the exercise before expiration.